T-cell Prolymphocytic Leukemia Survival Rate

The five-year survival rate for T-PLL remains low, though data suggests potential for long-term control in a subset of patients. For instance, patients who achieve a complete response to initial therapy and are eligible for further consolidation may have a three-year overall survival rate near 50%. Here, we provide population-based data on T-PLL incidence, survival, and treatment patterns within Germany, complementing the sparse existing epidemiological data and contributing to a...

In this large multi-center series, with comprehensive clinical data, we evaluated survival and therapeutic outcomes in T-PLL patients, with a focus on identification of prognostic subgroups of T-PLL, that will inform future investigations into the biology and treatment of this disease. According to various studies, the median survival time for patients with T-PLL is typically less than two years. However, some patients may live longer with aggressive treatment.

This article explores the characteristics of T-PLL, its treatment approaches, factors influencing survival, and current survival statistics, along with insights into ongoing research. Recent studies show a one-year survival rate of about 60% for T-PLL patients. This is hopeful, as it means many can live past the first year with the right treatment.

In children with T-cell acute lymphoblastic leukemia (T-ALL), the most common form, about 75% remain cancer-free after five years. Adults face tougher odds, and rarer subtypes like T-cell prolymphocytic leukemia carry significantly shorter survival times. Here, we provide population-based data on T-PLL incidence, survival, and treatment patterns within Germany, complementing the sparse existing epidemiological data and contributing to a broader knowledge of disease patterns.

Survival remains poor for T-cell prolymphocytic leukemia, though treatment in recent years, associated with access to novel therapies, and management at academic medical centers is associated with improved outcomes. Using the National Cancer Database (NCDB), we aimed to analyze patient characteristics, transplant selection predictors, and survival in T-PLL. Methods: We conducted a retrospective cohort analysis of T-PLL patients aged 18 or older from the NCDB (20042020).